Lantern Pharma Inc. LTRN
are an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and timeline
of oncology drug discovery and development. Our development portfolio includes three clinical stage oncology focused product candidates
and consists of small molecules that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds
that we are developing with the assistance of our proprietary A.I. platform and our biomarker driven approach. Our A.I. platform, known
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| R&D | $11.5M | $16.1M | $11.9M | $8.6M | $7.6M | $2.2M | — | — |
| SG&A | $6.5M | $6.1M | $6.0M | $5.8M | $5.0M | $3.7M | $1.5M | — |
| Total operating expenses | $18.0M | $22.2M | $17.9M | $14.4M | $12.6M | $5.9M | $2.4M | — |
| Operating income | -$18.0M | -$22.2M | -$17.9M | -$14.4M | -$12.6M | — | — | — |
| Net income | -$17.1M | -$20.8M | -$16.0M | -$14.3M | -$12.4M | -$5.9M | -$2.4M | — |
| EPS, basic | -1.57 | -1.93 | -1.47 | -1.31 | -1.13 | — | — | — |
| EPS, diluted | -1.57 | -1.93 | -1.47 | -1.31 | -1.13 | -1.37 | -1.23 | — |
| Shares, diluted (wtd. avg.) | $10.9M | $10.8M | $10.8M | $10.9M | $10.9M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.4M | $7.5M | $21.9M | $37.2M | $51.5M | $19.2M | $1.2M | $445.2K |
| Short-term investments | $5.7M | $16.5M | $19.4M | $18.0M | $19.2M | — | — | — |
| Total current assets | $10.8M | $25.2M | $43.3M | $58.7M | $72.7M | $20.2M | $1.2M | — |
| Property, plant and equipment | $31.9K | $47.4K | $52.1K | $48.0K | $30.2K | $21.5K | $8.8K | — |
| Total assets | $11.0M | $25.6M | $43.6M | $58.8M | $74.0M | $20.4M | $1.4M | — |
| Accounts payable | $4.4M | $4.1M | $2.5M | $2.7M | $2.2M | $552.3K | — | — |
| Total current liabilities | $4.5M | $4.3M | $2.7M | $2.8M | $2.3M | $552.3K | $489.3K | — |
| Total liabilities | $4.5M | $4.4M | $2.7M | $2.8M | $2.4M | $660.8K | $489.3K | — |
| Retained earnings | -$93.1M | -$76.0M | -$55.2M | -$39.3M | -$25.0M | -$12.7M | -$6.8M | — |
| Total equity | $6.5M | $21.2M | $40.9M | $56.0M | $71.6M | $19.7M | $943.3K | -$201.8K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.7M | -$17.8M | -$14.3M | -$12.8M | -$10.6M | -$5.7M | -$2.1M | — |
| Depreciation and amortisation | — | — | $14.6K | $10.1K | $6.8K | $3.4K | $1.6K | — |
| Stock-based compensation | $651.0K | $652.0K | $1.0M | $1.2M | $961.5K | — | — | — |
| Capital expenditure | $1.7K | $12.6K | $18.7K | $27.8K | $15.5K | — | — | — |
| Investing cash flow | $11.1M | $3.4M | -$930.2K | $179.3K | -$19.5M | -$16.1K | -$5.7K | — |
| Financing cash flow | $1.5M | $66.7K | -$500.0K | -$2.2M | $63.4M | $23.7M | $2.9M | — |
| Buybacks | — | — | $500.0K | $2.5M | $939.7K | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-019713.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |